FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to obstetrics and can be used in the 3rd trimester of pregnancy for predicting clinical effectiveness in severe gestosis. Substance of the invention consists in that starting from 28 weeks of pregnancy peripheral venous blood of a woman suffering from severe gestosis is analysed for the content of CD16+CD3-cells. If the related values are less than 9%, conventional therapy of severe gestosis is predicted as efficient, while the value 9% or more show the absence of clinical effectiveness in gestosis.;EFFECT: application of the method allows predicting effectiveness of conventional therapy in severe gestosis from 28 weeks of pregnancy with high accuracy, sensitivity and specificity that enable to determine approach to further prenatal care and delivery, to reduce risk of fetal pathology, maternal and perinatal mortality.;1 tbl, 3 ex
展开▼
